Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
María Asunción Esteve-Pastor, José Miguel Rivera-Caravaca, Martín Ruiz-Ortiz, Javier Muñiz, Inmaculada Roldán-Rabadán, Déborah Otero, Raquel López-Gálvez, Ángel Cequier, Vicente Bertomeu-Martínez, Lina Badimón, Manuel Anguita, Gregory Y.H. Lip & Francisco Marín. (2022) A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Expert Opinion on Pharmacotherapy 23:12, pages 1457-1465.
Read now
Read now
Alpesh N. Amin, Scott B. Robinson, Bruce D. Bowdy, Yonghua Jing, Bernadette H. Johnson & Daniel P. Wiederkehr. (2016) Relationship of hospital-associated bleeding with length of stay and total hospitalization costs in patients hospitalized for atrial fibrillation. Journal of Medical Economics 19:5, pages 490-496.
Read now
Read now
Mikhail S Dzeshka & Gregory YH Lip. (2015) Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 16:17, pages 2661-2678.
Read now
Read now
Alpesh Amin, Michael Stokes, Dinara Makenbaeva, Daniel Wiederkehr, Ning Wu & John H. Lawrence. (2014) Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. Journal of Medical Economics 17:11, pages 771-781.
Read now
Read now
Articles from other publishers (4)
Ylenia Ingrasciotta, Andrea Fontana, Anna Mancuso, Valentina Ientile, Janet Sultana, Ilaria Uomo, Maurizio Pastorello, Paolo Calabrò, Giuseppe Andò & Gianluca Trifirò. (2021) Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. Pharmaceuticals 14:4, pages 290.
Crossref
Crossref
María Asunción Esteve-Pastor, José Miguel Rivera-Caravaca, Vanessa Roldán, Esteban Orenes-Piñero, Giulio Francesco Romiti, Imma Romanazzi, Ying Bai, João Carmo, Marco Proietti, Francisco Marín & Gregory Y.H. Lip. (2018) Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated “Real-World” in Patients With Atrial Fibrillation. The American Journal of Cardiology 122:5, pages 785-792.
Crossref
Crossref
María Asunción Esteve-Pastor, José Miguel Rivera-Caravaca, Vanessa Roldán, Vicente Vicente, Giulio Francesco Romiti, Imma Romanazzi, Marco Proietti, Mariano Valdés, Francisco Marín & Gregory Y.H. Lip. (2018) Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology 254, pages 125-131.
Crossref
Crossref
Paul T. Kocis, Guodong Liu, Dinara Makenbaeva, Jeffrey Trocio, Diana Velott, JoAnn B. Trainer, Younos Abdulsattar, Marta I. Molina & Douglas L. Leslie. (2016) Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation. Drugs - Real World Outcomes 3:2, pages 165-173.
Crossref
Crossref